Navigation Links
Performance-enhancing drug use more prevalent than Type 1 diabetes or HIV infection
Date:12/17/2013

Chevy Chase, MD A new Scientific Statement issued today by The Endocrine Society represents a comprehensive evaluation of available information on the prevalence and medical consequences of the use of performance-enhancing drugs (PEDs). The statement highlights the clinical pharmacology, adverse effects and detection of many substances often classified as PEDs, identifies gaps in knowledge and aims to focus the attention of the medical community and policymakers on PED use as an important public health problem.

PEDs are synonymous with the names of certain elite athletes who have been accused of using illegal substances to gain a competitive edge, but in reality professional athletes make up only a small fraction of the nation's 3 million PED users. Most users are non-athlete weightlifters who are more focused on personal appearance, in that they want to look leaner and more muscular. But according to the Society's new statement, PED use can take a heavy and dangerous toll on personal health.

"There is a widespread misperception that PED use is safe or that adverse effects are manageable," said Shalender Bhasin, MD, Director, Research Program in Men's Health: Aging and Metabolism, at the Brigham and Women's Hospital, and chair of the task force that developed the statement. "The truth is, PED use has been linked to increased risk of death and a wide variety of cardiovascular, psychiatric, metabolic, renal and musculoskeletal disorders."

There are several categories of PEDs, but the most frequently used substances are lean mass builders which are generally anabolic drugs that increase muscle mass and/ or reduce fat mass. By far the most prevalent illicit PEDs are anabolic-androgenic steroids (AAS), followed by human growth hormone, insulin-like growth factor-1 (IGF-1), insulin, stimulants, erythropoietin, diuretics and even thyroid hormone.

PED users at greatest risk for adverse effects are those who develop a dependence on the drugs and accumulate many years of exposure. According to the statement, nearly a third of AAS users will develop AAS dependence and about 1 million men have experienced AAS dependence at some time.

PED use can result in infertility, gynecomastia, sexual dysfunction, hair loss, acne and testicular atrophy. Furthermore, athletes and non-athlete weightlifters that use PEDs often engage in other high-risk health behaviors including concomitant use of other drugs such as alcohol and opiates with AAS. AAS users may be more susceptible to rage, antisocial and violent behaviors, and suicide.

"The use of performance-enhancing drugs is far more prevalent than is generally believed and deserves substantially greater investigation of its medical consequences, mechanisms, prevention and treatment," said Harrison G. Pope, Jr. of McClean Hospital at the Harvard Medical School in Belmont, MA, and another author of the statement. "Long-term observational studies (registries) to determine the health risks associated with PED use are a public health imperative."

Much of the national effort has focused on measures to detect, punish and shame elite athletes in the hope that these measures would discourage PED use by the rank-and-file PED user, who is not an athlete. The empiric experience of the past 20 years suggests that this approach has had very limited success. The statement emphasizes that PED use by athletes and non-athlete weightlifters are two distinct cultural phenomena; these two categories of PED users differ in their motivation to use PEDs and in their sociodemographic profile. The Position Statement makes the point that the PED use by non-athlete weightlifters is a major public health problem associated with potentially serious adverse health consequences.

The statement highlights several obstacles to better appreciating the adverse effects of PEDs. These include:

  • Randomized trials of PED use, in the does that athletes and non-athlete weightlifters typically use them, will never be possible because of ethical concerns. Most evidence of medical consequences of PED use come from animal models, case-control studies, case reports, and retrospective surveys;
  • Since widespread illicit PED use did not appear in the general population until the 1980s and 1990s, the great majority of PED users are still under the age of 50. As such, this population has not yet reached the age of risk for a range of diseases, such as cardiovascular problems, that often arise later in life;
  • PED use is usually covert. People are less apt to disclose PED use than other forms of drug use. In one study, 56 percent of PED users reported that they never disclosed their use to any physician.


'/>"/>

Contact: Aaron Lohr
alohr@endocrine.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related biology news :

1. Brief exposure to performance-enhancing drugs may be permanently remembered by muscles
2. Microplastic pollution prevalent in lakes too
3. Potent human toxins prevalent in Canadas freshwaters
4. Caution to pregnant women on red meat diabetes link
5. Newly discovered human peptide may become a new treatment for diabetes
6. Human stem cells used to elucidate mechanisms of beta-cell failure in diabetes
7. New look identifies crucial clumping of diabetes-causing proteins
8. Brain may play key role in blood sugar metabolism and development of diabetes
9. Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication
10. UC Davis researchers discover a biological link between diabetes and heart disease
11. Lifestyle, age linked to diabetes-related protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/15/2016)... York , March 15, 2016 ... market report published by Transparency Market Research "Digital Door Lock ... and Forecast 2015 - 2023," the global digital door lock ... 731.9 Mn in 2014 and is forecast to grow at ... Growth of micro, small and medium enterprises (MSMEs) across the ...
(Date:3/14/2016)... MELBOURNE, Florida , March 14, 2016 ... on the growing mobile commerce market, announces the airing of ... York channels starting the week of March 21 st . ... and CNBC, including its popular Squawk on the Street show. ... company focused on the growing mobile commerce market, announces the ...
(Date:3/11/2016)... HANOVER, Germany , March 11, 2016 ... - Cross reference: Picture is available at AP Images ( ... scanner from DERMALOG will be used to produce the new refugee ... of other biometric innovations, at CeBIT in Hanover ... LF10 scanner from DERMALOG will be used to produce the new ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
(Date:4/26/2016)... (PRWEB) , ... April 26, 2016 , ... The ... has been selected as one of three finalists for the European Inventor Award 2016 ... annual innovation prize will be announced at a ceremony in Lisbon on June 9th. ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a biopharmaceutical research and ... Healthy investor interest drove significant oversubscription of the original $1.5M target. The ... to the advanced preclinical stages. , Chief Executive Officer and President, Darryl Sampey ...
(Date:4/26/2016)... ... April 26, 2016 , ... The Institute ... its first round of pre-proposal competition for scientific grants. , The IVS funds ... ideas with the highest potential to replace paradigms that have outlived their usefulness. ...
Breaking Biology Technology: